Arun Swaminathan | Source | Chief Executive Officer at Coya Therapeutics

Arun Swaminathan, Ph.D., has over 20 years of hands-on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. He possesses a
demonstrated history of prospecting, evaluating, structuring, and closing company validating transactions that augment both organizational and shareholder value.

Prior to joining Coya, Arun served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) where he was responsible for all business development. Within 1 year of joining Actinium, he successfully moved forward negotiations to closure and executed a $452M deal with $35M upfront. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) where he spearheaded over $6B in deals, including deals with two of the top 10 global pharma companies and a $1B+ deal within the first year of assuming the role of CBO. Prior to this, he co-founded and served as CEO of Lynkogen Inc, a pre-clinical stage biotech.

Arun began his career in clinical development and commercial roles of increasing responsibility at BristolMyers Squibb and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.